QIAGEN Launches Predictive Therascreen Pitx2 Test in Europe to Guide Treatment in High-Risk Breast Cancer
Qiagen N.V. Common Shares (QGEN)
Last qiagen n.v. common shares earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corporate.qiagen.com/investor-relations
Company Research
Source: Business Wire
Novel DNA methylation assay provides insights for individualized chemotherapy selection HILDEN, Germany--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the European launch of its novel therascreen PITX2 RGQ PCR Kit, the first clinically validated DNA methylation assay that helps predict the response of certain high-risk breast cancer patients to anthracycline-based chemotherapy. The CE-IVD marked assay is QIAGEN’s first epigenetic test in breast cancer, as well as the latest addition to QIAGEN’s broad portfolio of therascreen tests delivering individualized genetic insights to guide medical decisions in lung, colorectal and other cancers. More than 460,000 women in Europe are newly diagnosed with breast cancer each year, with about 50% characterized as high-risk for disease recurrence. Anthracycline-based chemotherapy is the standard of care, yet no
Show less
Read more
Impact Snapshot
Event Time:
QGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QGEN alerts
High impacting Qiagen N.V. Common Shares news events
Weekly update
A roundup of the hottest topics
QGEN
News
- deepull unveils 1 hour, direct-from-blood multiplex PCR test for 95% of sepsis-causing pathogens at ESCMID 2024 [Yahoo! Finance]Yahoo! Finance
- QIAGEN expands tuberculosis portfolio with new NGS Panel to support real-time surveillance and combat antimicrobial resistance [Yahoo! Finance]Yahoo! Finance
- QIAGEN expands tuberculosis portfolio with new NGS Panel to support real-time surveillance and combat antimicrobial resistanceGlobeNewswire
- Unveiling Qiagen (QGEN) Q1 Outlook: Wall Street Estimates for Key Metrics [Yahoo! Finance]Yahoo! Finance
- Cervical Dysplasia Market Report 2024: Global Trends, Forecast and Competitive Analysis 2018-2023 and 2024-2030 [Yahoo! Finance]Yahoo! Finance
QGEN
Earnings
- 2/6/24 - Miss
QGEN
Sec Filings
- 3/11/24 - Form 20-F
- 3/11/24 - Form IRANNOTICE
- 2/9/24 - Form SC
- QGEN's page on the SEC website